Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
Status:
Completed
Trial end date:
2021-06-24
Target enrollment:
Participant gender:
Summary
This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study
to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor
receptor 2 protein (HER2)-positive node positive or high risk node negative breast cancer
participants with regimen consisting of doxorubicin and cyclophosphamide followed by either
paclitaxel or docetaxel (AC-TH Regimen) or a regimen consisting of docetaxel and carboplatin
(TCH Regimen) in Indian population.